Non-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review

Jeanette M Tetrault, Jenna L Butner, Jeanette M Tetrault, Jenna L Butner

Abstract

Over the past few decades, there has been a rise in the non-medical use of prescription opioids, which has now reached epidemic proportions in the United States. In some cases, this non-medical use progresses to prescription opioid use disorder, heroin use, injection, and inhalation drug use, all of which may have further devastating consequences. The purpose of this review article is to discuss the epidemiology of the non-medical use of prescription opioids; discuss the potential progression to subsequent prescription opioid use disorder; review the state and national efforts in development to address addiction and diversion in the United States; discuss treatment options; and, lastly, to evaluate the impact of the related stigma to the development of opioid use disorder. Many unanswered questions remain, and we will explore future possibilities in how the medical community can play a role in curbing this epidemic.

Keywords: opioid agonist treatment; opioid use disorder; prescription opioid use disorder; substance use disorder.

Figures

Figure 1
Figure 1
Past Month Illicit Drug Use among Persons Aged 12 or Older: 2013. Illicit Drugs include marijuana/hashish, cocaine (including crack), heroin, hallucinogens, inhalants, or prescription-type psychotherapeutics used nonmedically. Image courtesy of SAMHSA.
Figure 2
Figure 2
Source Where Pain Relievers Were Obtained for Most Recent Nonmedical Use among Past Year Users Aged 12 or Older: 2012-2013. 1Other includes the sources "Wrote Fake Prescription," "Stole from Doctor's Office/Clinic/Hospital/ Pharmacy," and "Some Other Way." Note: The percentages do not add to 100 percent due to rounding. Image courtesy of SAMHSA.
Figure 3
Figure 3
Prescription Opioid Sales, Deaths and Substance Abuse Treatment Admissions. Image courtesy of SAMHSA.

References

    1. Imtiaz S, Shield KD, Fischer B, Rehm J. Harms of prescription opioid use in the United States. Subst Abuse Treat Prev Policy. 2014;9:43.
    1. Kanouse AB, Compton P. The epidemic of prescription opioid abuse, the subsequent rising prevalence of heroin use, and the federal response. J Pain Palliat Care Pharmacother. 2015;29(2):102–114.
    1. Katz NP, Adams EH, Chilcoat H, Colucci RD, Comer SD, Goliber P. et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain. 2007;23(8):648–660.
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
    1. Gilson AM, Joranson DE. U.S. policies relevant to the prescribing of opioid analgesics for the treatment of pain in patients with addictive disease. Clin J Pain. 2002;18(4 Suppl):S91–S98.
    1. Caudill-Slosberg MA, Schwartz LM, Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain. 2004;109(3):514–519.
    1. Olsen Y, Daumit GL, Ford DE. Opioid prescriptions by u.s. primary care physicians from 1992 to 2001. J Pain. 2006;7(4):225–235.
    1. O’Connor PG, Nyquist JG, McLellan AT. Integrating addiction medicine into graduate medical education in primary care: the time has come. Ann Intern Med. 2011;154(1):56–59.
    1. SAMHSA. Results from the 2013 national survey on drug use and health: summary of national findings. NSDUH Series H-48, HHS Publication No. (SMA) 14-4863. Rockville, MD: SAMHSA; 2014.
    1. Tetrault JM, Desai RA, Becker WC, Fiellin DA, Concato J, Sullivan LE. Gender and non-medical use of prescription opioids: results from a national US survey. Addiction. 2008;103(2):258–268.
    1. Becker WC, Sullivan LE, Tetrault JM, Desai RA, Fiellin DA. Non-medical use, abuse and dependence on prescription opioids among U.S. adults: psychiatric, medical and substance use correlates. Drug Alcohol Depend. 2008;94(1-3):38–47.
    1. Manubay J, Davidson J, Vosburg S, Jones J, Comer S, Sullivan M. Sex differences among opioid-abusing patients with chronic pain in a clinical trial. J Addict Med. 2015;9(1):46–52.
    1. Atluri S, Sudarshan G, Manchikanti L. Assessment of the trends in medical use and misuse of opioid analgesics from 2004 to 2011. Pain Physician. 2014;17(2):E119–E128.
    1. CDC. Vital signs: overdoses of prescription opioid pain relievers and other drugs among women--United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2013;62(26):537–542.
    1. Clausen T. Coherent long-term treatment approaches–superior in the treatment of opioid dependence. Addiction. 2015;110(6):1006–1007.
    1. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Sys Rev. 2011;(8):CD004145.
    1. Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs. 2012;72(2):217–228.
    1. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Sys Rev. 2009;(3):CD002209.
    1. Fiellin DA, Pantalon MV, Pakes JP, O’Connor PG, Chawarski M, Schottenfeld RS. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse. 2002;28(2):231–241.
    1. Fudala PJ, Bridge TP, Herbert S, Williford WO, Chiang CN, Jones K. et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949–958.
    1. Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PJ. Primary care–based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947–1954.
    1. Moore BA, Fiellin DA, Barry DT, Sullivan LE, Chawarski MC, O’Connor PJ. et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007;22(4):527–530.
    1. Tetrault JM, Fiellin DA. Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals. Drugs. 2012;72(2):217–228.
    1. Ingersoll K. Motivational interviewing for substance use disorder. UpToDate [Internet] 2015. Available from: .
    1. Fiellin DA, Pantalon MV, Chawarski MC, Moore BA, Sullivan LE, O’Connor PG. et al. Counseling plus buprenorphine–naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355(4):365–374.
    1. Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. Subst Abus. 2015;36(2):240–253.
    1. Gugelmann HM, Perrone J. Can prescription drug monitoring programs help limit opioid abuse? JAMA. 2011;306(2):258–259.
    1. Office of National Drug Control Policy. Epidemic: responding to America’s prescription drug abuse crisis. Washington, DC: Office of National Drug Control Policy; 2011.
    1. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription Drug monitoring programs and death rates from drug overdose. Pain Med. 2011;12(5):747–754.
    1. Starrels JL, Becker WC, Alford DP, Kapoor A, William AR, Turner BJ. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med. 2010;152(11):712–720.
    1. Chou R, Fanciullo GJ, Fine PG, Miaskowski C, Passik SD, Portenoy RK. Opioids for chronic noncancer pain: prediction and identification of aberrant drug-related behaviors: a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J Pain. 2009;10(2):131–146.
    1. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432–442.
    1. Portenoy RK. In: Lowinson and Ruiz’s Substance abuse: a comprehensive textbook. 5th ed. Ruiz P, Strain E, editors. Philadelphia, PA: Lippincott Williams and Wilkins; 2011. Acute and chronic pain; pp. 695–720.
    1. Dwyer K, Walley AY, Langlois BK, Mitchell PM, Nelson KP, Cromwell J. et al. Opioid education and nasal naloxone rescue kits in the emergency department. West J Emerg Med. 2015;16(3):381–384.
    1. Hoffmann DE, Tarzian AJ. Achieving the right balance in oversight of physician opioid prescribing for pain: the role of state medical boards. J Law Med Ethics. 2003;31(1):21–40.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel